Abbott Reports Fourth-Quarter 2017 Results

Go back to Abbott Reports Fourth-Quarter 2017 Results

Abbott Labs (ABT) PT Raised to $68 at Leerink Partners

January 25, 2018 7:16 AM EST

Leerink Partners raised its price target on Abbott Labs (NYSE: ABT) to $68.00 (from $60.00) while maintaining a Outperform rating.

... More

Abbott Labs (ABT) PT Raised to $71 at Stifel

January 24, 2018 4:42 PM EST

Stifel raised its price target on Abbott Labs (NYSE: ABT) to $71.00 (from $63.00) while maintaining a Buy rating following strong Q4 results.

Analyst Rick Wise said the company has significant and sustainable momentum heading into 2018.

... More

Abbott Labs (ABT) PT Raised to $67 at Evercore ISI

January 24, 2018 12:34 PM EST

Evercore ISI raised its price target on Abbott Labs (NYSE: ABT) to $67.00 (from $64.00) while maintaining a Outperform rating.

The firm raised FY2018 EPS from $2.82 to $2.87, trimmed FY 2019 from $3.23 to $3.22 and raised FY 2020 from $3.55 to $3.56.

... More

Abbott (ABT) Tops Q4 EPS by 1c, Offers FY18 Guidance

January 24, 2018 7:48 AM EST

Abbott (NYSE: ABT) reported Q4 EPS of $0.74, $0.01 better than the analyst estimate of $0.73. Revenue for the quarter came in at $7.6 billion versus the consensus estimate of $7.39 billion.

GUIDANCE:

Abbott sees FY2018 EPS of $2.80-$2.90, versus the consensus of $2.83.

Abbott is... More